Search intent and key terms

Primary keyword: Venomics AI $2.7 million pre-seed
Intent: News and commercial investigation: founders and investors tracking verified Indian biotech, drug-discovery and deeptech funding.

Direct answer

Bengaluru-based Venomics AI has raised $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio participating. The Indian Institute of Science spinout is building a venom-to-therapeutics discovery platform that combines biological datasets, computational prioritisation and laboratory screening.

The funding announcement was reported on 5 November 2026 and is the latest uncovered verified Indian startup round in today’s scan. No valuation was disclosed in the reviewed sources. The Best CS Firm In India funding lens separates promising scientific claims from validated candidates, owned data, regulatory progress and financing evidence.

Deal snapshot

What Venomics AI is building

Animal venoms contain diverse bioactive molecules evolved to act on biological targets. Venomics AI is creating a “Venom Atlas” and using computational methods to prioritise molecules for experimental screening. The goal is to turn selected compounds into potential therapeutic leads.

The company was founded by IISc professor and venom researcher Kartik Sunagar and machine-learning researcher Vinay Prabhu. Its model depends on both defensible biological data and repeatable wet-lab validation; software predictions alone do not establish a drug candidate.

Planned use of funds

• Expand the Venom Atlas molecular dataset.
• Strengthen computational and laboratory screening capabilities.
• Validate and optimise promising molecular candidates.
• Hire across venom biology, computational science and drug discovery.
• Advance the integrated discovery platform toward repeatable programmes.

Why the round is founder-relevant

Scientific depth plus platform leverage

The investment thesis combines a specialist biological domain with a platform that could support multiple target and therapeutic programmes. That creates leverage only if data provenance, assay quality and validation are consistent.

India-origin research with global potential

The IISc origin and India’s biodiversity create a differentiated starting point, while drug discovery ultimately requires global-quality IP, ethics, biosafety, preclinical and partnership execution.

Founder diligence lessons

• Distinguish a molecular hit, validated lead, preclinical candidate and approved medicine.
• Document source permissions, collection protocols and chain of custody for biological material.
• Clarify IISc, founder, employee and collaborator IP ownership in writing.
• Define dataset provenance, model rights and access controls.
• Use reproducible assay results rather than promotional metrics.
• Link each funding milestone to a scientific decision point and runway.
• Keep grant, investor and press claims consistent with the data room.

What the next data room should prove

Founder / Business Takeaway

Venomics AI’s round reflects interest in Indian science-led platforms with proprietary data and laboratory validation. The durable company will be built by proving ownership, reproducibility and milestone discipline—not by computational promise alone.

Sources and verification

Frequently Asked Questions

Suggested internal links